Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275128 | 0.83 | GAA (0.30) | GAAMAPT | |
| SCHEMBL13890497 | 0.80 | GCK (0.32) | MAPTMEN1KMT2A | |
| SCHEMBL13515950 | 0.80 | — | — | |
| SCHEMBL4187872 | 0.80 | — | — | |
| SCHEMBL13516244 | 0.79 | — | — | |
| SCHEMBL13875591 | 0.79 | GAA (0.32) | GAAMAPTALDH1A1 | |
| SCHEMBL1542675 | 0.77 | POLB (0.54) | POLBCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29111979 | 0.74 | GAA (0.31) | HIF1AGAAMAPTALDH1A1RECQL | |
| SCHEMBL3652875 | 0.72 | CA1 (0.46) | POLBCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3586302 | 0.71 | ALDH1A1 (0.48) | POLBGAAMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007064553-A2 | THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CX3CR1 | POLB 4297/4885CYP1A2 3367/4885CYP2D6 2761/4885 |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | POLB 4548/4885CYP1A2 2025/4885CYP2D6 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.